Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this ...
MarketBeat on MSN
5 high-yield stocks and ETFs to buy and hold for the next decade
Key Points Interested in AbbVie Inc.? Here are five stocks we like better. Five high-yield names spanning pharmaceuticals, ...
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a ...
These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.
Dividend stocks with long track records of dividend increases tend to have stable underlying businesses. That's definitely ...
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...
Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; oncology increased $1.47 PMPM with 7.3% higher use. Dermatology spend rose $1.40 ...
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results